Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 16.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,500 shares of the company's stock after purchasing an additional 4,400 shares during the period. Handelsbanken Fonder AB's holdings in Vaxcyte were worth $2,579,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of PCVX. Blue Trust Inc. lifted its stake in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares in the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after acquiring an additional 635 shares during the period. Nomura Asset Management Co. Ltd. bought a new position in shares of Vaxcyte in the third quarter worth about $92,000. Signaturefd LLC grew its position in shares of Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company's stock worth $120,000 after purchasing an additional 358 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in Vaxcyte during the 4th quarter valued at approximately $161,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Stock Performance

Vaxcyte stock traded down $1.20 during trading on Friday, reaching $73.02. The company had a trading volume of 2,530,601 shares, compared to its average volume of 1,156,013. The firm has a market capitalization of $9.10 billion, a PE ratio of -15.87 and a beta of 0.98. The firm's 50-day simple moving average is $84.86 and its 200 day simple moving average is $94.74. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06.

Remove Ads

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. Analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Upgrades and Downgrades

PCVX has been the topic of several research analyst reports. The Goldman Sachs Group started coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 target price on the stock. Guggenheim reaffirmed a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday. Needham & Company LLC reissued a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $147.50.

Insider Buying and Selling

In related news, COO Jim Wassil sold 8,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $92.49, for a total value of $739,920.00. Following the completion of the transaction, the chief operating officer now directly owns 205,695 shares of the company's stock, valued at approximately $19,024,730.55. This represents a 3.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the sale, the chief executive officer now directly owns 450,301 shares in the company, valued at approximately $41,630,327.45. This trade represents a 3.22 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 76,616 shares of company stock worth $6,766,481. Insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.